Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-072789
Filing Date
2025-05-15
Accepted
2025-05-15 16:45:37
Documents
56
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q inkt-20250331.htm   iXBRL 10-Q 970371
2 EX-31.1 inkt-ex31_1.htm EX-31.1 16959
3 EX-31.2 inkt-ex31_2.htm EX-31.2 16923
4 EX-32.1 inkt-ex32_1.htm EX-32.1 11682
  Complete submission text file 0000950170-25-072789.txt   4607609

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inkt-20250331.xsd EX-101.SCH 825187
59 EXTRACTED XBRL INSTANCE DOCUMENT inkt-20250331_htm.xml XML 588544
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40908 | Film No.: 25954613
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)